Shire PLC(SHPG)- NASDAQ
  • Thu, Aug. 18, 8:46 AM
    • Raptor Pharmaceuticals (NASDAQ:RPTP) is ahead 16% premarket on robust volume on the buzz that several companies are eyeing the Novato, CA firm, including Shire plc (NASDAQ:SHPG) who alleged has already bid $800M and Retrophin (NASDAQ:RTRX), founded by biotech bad boy Martin Shkreli.
    • Raptor focuses its development efforts in rare diseases. Its pipeline includes programs in Huntington's disease, cancer, cystic fibrosis and mitochondrial diseases.
    • It currently markets two products: PROCYSBI (cysteamine bitartrate) delayed-release capsules for nephropathic cystinosis and QUINSAIR (aerosolized form of levofloxacin) for the management of chronic pulmonary infections.
    | Thu, Aug. 18, 8:46 AM | 2 Comments
  • Fri, Jun. 3, 7:03 AM
    • Shire plc (NASDAQ:SHPG) completes its merger with Baxalta (NYSE:BXLT). The combined company has over 22,000 employees in more than 100 countries and is expected to deliver over $20B in revenue by 2020. The transaction should be accretive to non-GAAP EPS in 2017.
    • Baxalta shareholders received $18 in cash plus 0.1482 of a Shire ADS for each Baxalta share.
    • Read now A Deep Dive Into Shire's Business
    | Fri, Jun. 3, 7:03 AM | 30 Comments
  • Fri, May 27, 9:27 AM
    • As expected, Shire plc (NASDAQ:SHPG) shareholders voted overwhelmingly in favor of the merger with Baxalta (NYSE:BXLT). At a special meeting, 93.8% of the votes cast, representing 75.5% of Shire's outstanding shares, backed the deal.
    • The positive vote from Baxalta's side was also overwhelmingly in favor with 98.9% of shares backing the marriage.
    • Previously: Shire takes out Baxalta for $32B (Jan. 11)
    | Fri, May 27, 9:27 AM | 1 Comment
  • Fri, Apr. 15, 3:37 AM
    • Baxalta (NYSE:BXLT) shares fell more than 5% in extended trading after the company announced a special shareholders meeting on May 27 to vote on its merger with Shire (NASDAQ:SHPG).
    • Baxalta would benefit from a lower tax rate if taken over by Shire, and the enlarged company could generate $20B in sales by 2020, with as many as 30 new drugs to launch over five years.
    • Update: On May 23, preliminary results show that holders of 6.1% of BXLT shares (41,803,203) elected to receive Shire ordinary shares instead of Shire ADSs. Shires' offer for Baxalta is $18 in cash plus either 0.1482 of a Shire ADS (1 ADS = three ordinary shares) or 0.4446 of a Shire ordinary share.
    | Fri, Apr. 15, 3:37 AM | 12 Comments
  • Wed, Apr. 6, 3:08 PM
    • Shire (SHPG +4.5%) expects the deal with Baxalta (BXLT +6.5%) will proceed as originally announced on Jan. 11. As before, the merger is expected to close by mid-2016.
    • Source: Press Release
    | Wed, Apr. 6, 3:08 PM | 9 Comments
  • Tue, Apr. 5, 2:50 PM
    | Tue, Apr. 5, 2:50 PM | 15 Comments
  • Fri, Jan. 22, 9:47 AM
    • Shire plc (SHPG +3.1%) completes its $5.9B acquisition of (DYAX), whose shareholders will receive $37.30 per share in cash plus potentially $4 more via a non-tradable contingent value right (CVR) related to the regulatory clearance of DX-2930 for the treatment of hereditary angioedema (HAE). A Phase 3 study should be completed in December.
    • Previously: Shire buys Dyax for $5.9B in cash (Nov. 2, 2015)
    | Fri, Jan. 22, 9:47 AM | 7 Comments
  • Wed, Jan. 20, 3:46 PM
    • Tomorrow is the special meeting of (DYAX +0.1%) shareholders at which they will vote on Shire's (SHPG -1.7%) $37.30 per share bid ($5.9B). Overwhelming support is expected.
    • Previously: Shire buys Dyax for $5.9B in cash (Nov. 2, 2015)
    | Wed, Jan. 20, 3:46 PM
  • Mon, Jan. 11, 7:36 AM
    • It's official. Shire plc (NASDAQ:SHPG) acquires Baxalta (NYSE:BXLT) for $45.57 per share ($32B). Under the terms of the deal, Baxalta shareholders will receive $18 per share in cash plus 0.1482 Shire ADS. The deal represents a 13.9% premium to Baxalta's closing price on Friday. The transaction should close by mid-year.
    • BXLT is up 4% premarket while SHPG is up 1%.
    • SA Contributor Chris DeMuth, whose Rangeley Capital has a significant stake in Baxalta, says, "We support the transaction and think it will be a successful deal for both companies." Rangeley's Andrew Walker adds, "I think the deal makes plenty of sense. [It] is full and fair and there are substantial synergies to be had from cost cutting and tax improvement. Both sets of shareholders should be very happy."
    • Previously: Shire to announce Baxalta deal as early as Monday (Jan. 7)
    • Previously: Shire sweetens Baxalta bid, deal imminent (Dec. 22, 2015)
    | Mon, Jan. 11, 7:36 AM | 51 Comments
  • Thu, Jan. 7, 3:35 PM
    | Thu, Jan. 7, 3:35 PM | 19 Comments
  • Mon, Jan. 4, 4:05 AM
    • Shire (NASDAQ:SHPG) is in advanced talks to acquire Baxalta (NYSE:BXLT) for $46.50-$48 per share, or about $32B in cash and stock, excluding debt, Bloomberg reports.
    • Final details of the transaction are still being negotiated, but the two drugmakers are likely to announce a deal this week.
    • Baxalta would benefit from a lower tax rate if taken over by Shire, and the enlarged company would generate $20B in sales by 2020, with as many as 30 new drugs to launch over five years.
    • SHPG -1.5% premarket, BXLT +9% premarket.
    • Previously: Shire sweetens Baxalta bid, deal imminent (Dec. 22 2015)
    | Mon, Jan. 4, 4:05 AM | 1 Comment
  • Dec. 22, 2015, 4:23 PM
    • According to Reuters, Shire Plc (NASDAQ:SHPG) has made a sweetened offer for Baxalta (NYSE:BXLT) that values it in line with Baxalta's expectations, making a deal possible in the next few weeks. The new offer includes enough cash that raises the value of the bid to over $30B.
    • Previously: Shire plans to sweeten Baxalta bid by £8B (Dec. 20)
    | Dec. 22, 2015, 4:23 PM | 16 Comments
  • Dec. 20, 2015, 5:36 PM
    • As much as 40% of Shire's (NASDAQ:SHPG) rumored renewed bid for Baxalta (NYSE:BXLT) could be in cash.
    • £8B would bring the total value of a deal to  £20B.
    • Shire hopes to complete the deal by mid-January.
    • In August, Shire made an all-stock offer of £19.2B for Baxalta. Baxalta said the price was “nowhere near” the value the board was seeking. Since then, its shares fell from above $40/share to $31, but have since rebounded to $38.
    • Source: Sunday Times
    | Dec. 20, 2015, 5:36 PM | 29 Comments
  • Dec. 15, 2015, 8:32 AM
    | Dec. 15, 2015, 8:32 AM | 14 Comments
  • Dec. 11, 2015, 3:24 PM
    • The new offer could include a sizable cash component, reports Bloomberg, noting Baxalta (BXLT -0.8%) rejected Shire's (SHPG -2.1%) previous $30B all-stock bid.
    • That previous bid was 0.1687 shares in Shire ADRs for each share of Baxalta, valuing the target company at $45.23 (it's currently $37.45).
    • The combined company would generate $20B in sales by 2020, with as many as 30 new drugs launching over the next five years. There's the inversion angle, of course, and Baxalta projects a tax rate of 23% next year. The combined firm would have an effective tax rate of 16-17%, says Shire.
    • Previously: Reuters: Shire prepping new bid for Baxalta (Nov. 24)
    | Dec. 11, 2015, 3:24 PM | 10 Comments
  • Dec. 2, 2015, 5:40 PM
    • Dyax (NASDAQ:DYAX) is up 12.1% after hours, and ADRs for Shire (NASDAQ:SHPG) are up 1.5%, as the Hart-Scott-Rodino antitrust waiting period for Shire's acquisition of Dyax (DYAX) was ended today by the FTC.
    • Shire had entered into an agreement to buy Dyax for about $5.9B, or $37.30/share in cash. Dyax was most recently trading at $37.40 after hours.
    • In the deal, Dyax's shareholders could get additional value beyond the cash in a non-tradable contingent value right worth $4/share, depending on the approval of DX-2930.
    • Previously: Shire buys Dyax for $5.9B in cash (Nov. 02 2015)
    | Dec. 2, 2015, 5:40 PM | 5 Comments
Company Description
Shire Plc is a biopharmaceutical company, which focuses on developing and marketing innovative medicines for patients with rare diseases and other conditions. It engaged in the research, development, licensing, manufacturing, marketing, distribution and sale of innovative specialist medicines to... More
Sector: Healthcare
Industry: Drug Manufacturers - Major
Country: United Kingdom